Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients
- Author
- POLKINGHORNE, Kevan R1 ; MCMAHON, Lawrence P1 ; BECKER, Gavin J1
[1] Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia - Source
American journal of kidney diseases. 2002, Vol 40, Num 5, pp 990-995, 6 p ; ref : 22 ref
- ISSN
- 0272-6386
- Scientific domain
- Urology, nephrology
- Publisher
- Elsevier, Orlando, FL
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Analyse quantitative Anticoagulant Coagulation Factor Xa Daltéparine sodique Danaparoïde sodique Dose Enoxaparine sodique Homme Hémodialyse Héparine bas poids moléculaire Méthode alternative Pharmacocinétique Enzyme Epuration extrarénale Hydrolases Peptidases Serine endopeptidases
- Keyword (en)
- Quantitative analysis Anticoagulant Coagulation Factor Xa Dalteparin sodium Danaparoid sodium Dose Enoxaparin sodium Human Hemodialysis Low molecular weight heparin Alternative method Pharmacokinetics Enzyme Extrarenal dialysis Hydrolases Peptidases Serine endopeptidases
- Keyword (es)
- Análisis cuantitativo Anticoagulante Coagulation Factor Xa Dalteparina sódica Danaparoide sódico Dosis Enoxaparina sódica Hombre Hemodiálisis Heparina bajo peso molecular Método alternativo Farmacocinética Enzima Depuración extrarrenal Hydrolases Peptidases Serine endopeptidases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B27 Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy / 002B27B Intensive care medicine / 002B27B03 Emergency and intensive care: renal failure. Dialysis management
- Discipline
- Anaesthesia. Reanimation. Transfusion. Cell therapy and gene therapy
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 13993616
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1053/ajkd.2002.36331 
https://dx.doi.org/10.1053/ajkd.2002.36331
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/ajkd.2002.36331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:9:\"\u0000*\u0000jtitle\";s:35:\"American journal of kidney diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Am. j. kidney dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"990\";s:8:\"\u0000*\u0000epage\";s:3:\"995\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0272-6386\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"POLKINGHORNE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Kevan R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:19:\"MCMAHON, Lawrence P\";i:1;s:15:\"BECKER, Gavin J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:8:\"\u0000*\u0000place\";s:11:\"Orlando, FL\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/ajkd.2002.36331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:9:\"\u0000*\u0000jtitle\";s:35:\"American journal of kidney diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Am. j. kidney dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"990\";s:8:\"\u0000*\u0000epage\";s:3:\"995\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0272-6386\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"POLKINGHORNE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Kevan R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:19:\"MCMAHON, Lawrence P\";i:1;s:15:\"BECKER, Gavin J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:8:\"\u0000*\u0000place\";s:11:\"Orlando, FL\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/ajkd.2002.36331\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/ajkd.2002.36331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:9:\"\u0000*\u0000jtitle\";s:35:\"American journal of kidney diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Am. j. kidney dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"990\";s:8:\"\u0000*\u0000epage\";s:3:\"995\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0272-6386\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"POLKINGHORNE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Kevan R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:19:\"MCMAHON, Lawrence P\";i:1;s:15:\"BECKER, Gavin J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:8:\"\u0000*\u0000place\";s:11:\"Orlando, FL\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1053\/ajkd.2002.36331\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:9:\"\u0000*\u0000jtitle\";s:35:\"American journal of kidney diseases\";s:9:\"\u0000*\u0000stitle\";s:17:\"Am. j. kidney dis\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"990\";s:8:\"\u0000*\u0000epage\";s:3:\"995\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0272-6386\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"POLKINGHORNE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Kevan R\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:19:\"MCMAHON, Lawrence P\";i:1;s:15:\"BECKER, Gavin J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:142:\"Pharmacokinetic studies of Dalteparin (fragmin), enoxaparin (clexane), and danaparoid sodium (orgaran) in stable chronic hemodialysis patients\";s:8:\"\u0000*\u0000place\";s:11:\"Orlando, FL\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
